# David Kim

> David Kim is a Series A investor at DigiTx Partners backing Health Care and Medical Device. See 19 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [DigiTx Partners](https://shizune.co/investors/profile/digitx-partners)
- Location: San Francisco, United States
- Total investments: 19
- Last investment: May 2024
- Lead investor: 58%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/davidjkimmd
- Website: https://www.digitx.com

David Kim is a Series A investor at DigiTx Partners in San Francisco focused on Health Care and Medical Device. David J. Kim is based out of Brisbane, California and is the CEO & Managing Director of DigiTx Partners. David previously worked at Welldoc, Inc as a Board Observer. David J. Kim attended the Stanford University Graduate School of Business.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 47% |
| Medical Device | 5 | 26% |
| Artificial Intelligence | 5 | 26% |
| Medical | 4 | 21% |
| Software | 4 | 21% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 8 | 42% |
| Seed | 4 | 21% |
| Series B | 3 | 16% |
| Series C | 1 | 5% |
| Funding Round | 1 | 5% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 68% |
| Finland | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| StrokeDx | StrokeDx develops rapid and portable devices to transform how strokes are diagnosed. The company's full-time software engineering team works on novel algorithms using machine learning and AI approaches to fuel the diagnostic accuracy and imaging capabilities of the StrokeDx sensor. | $5M | Seed | May 23, 2024 |  |
| CardioSignal | We develop groundbreaking solutions for the detection of heart diseases. CardioSignal is a mobile application and a certified medical device for the detection of atrial fibrillation. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product byPrecordior. www.cardiosignal.com | $10M | Series A | Jan 23, 2024 |  |
| Rune Labs | Rune Labs is a software and data platform for neuromodulation and brain therapies of the future. The platform's software-as-a-service platform works with existing and emerging neuromodulation systems to manage complex therapies and get the most value out of available data. Their cloud-based software platform provides these therapy developersthe performance, scalability, and availability they need to run complex therapy algorithms across many patients, deliver precision medicine, and identify likely responders for clinical trials.Rune Labs was founded in 2018 and is headquartered in San Francisco, California. | $12M | Venture - Series Unknown | Jan 11, 2024 |  |
| Mightier | Mightier is a gaming platform and family program scientifically-proven to help kids regulate their emotions. It is a bioresponsive program that harnesses the mind-body connection to build emotional regulation in its players. Its program of bioresponsive video games, developed at Boston Children's Hospital and Harvard Medical School, aims tohelp children with behavioral and emotional challenges learn how to harness emotions in daily life.Mightier was founded in 2016 and is headquartered in Boston, Massachusetts. | $17M | Series B | Dec 13, 2021 |  |
| Rune Labs | Rune Labs is a software and data platform for neuromodulation and brain therapies of the future. The platform's software-as-a-service platform works with existing and emerging neuromodulation systems to manage complex therapies and get the most value out of available data. Their cloud-based software platform provides these therapy developersthe performance, scalability, and availability they need to run complex therapy algorithms across many patients, deliver precision medicine, and identify likely responders for clinical trials.Rune Labs was founded in 2018 and is headquartered in San Francisco, California. | $22.8M | Series A | Sep 16, 2021 |  |
| Nesos | Nēsos develops and commercializes electrical field treatments for neurological disorders. It is critically supported by expert clinical and scientific collaborators from leading academic institutions, including Stanford, Vall d'Hebron, Harvard, Mount Sinai, Feinstein Institute, University Of California, San Diego (UCSD), and the University OfCalifornia, San Francisco (UCSF). It was co-founded by Konstantinos Alataris and other neuroscientists. | $16.5M |  | Dec 10, 2020 |  |
| Nesos | Nēsos develops and commercializes electrical field treatments for neurological disorders. It is critically supported by expert clinical and scientific collaborators from leading academic institutions, including Stanford, Vall d'Hebron, Harvard, Mount Sinai, Feinstein Institute, University Of California, San Diego (UCSD), and the University OfCalifornia, San Francisco (UCSF). It was co-founded by Konstantinos Alataris and other neuroscientists. | $16.5M |  | Dec 10, 2020 |  |
| Eko Health | Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detectearlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com. | $65M | Series C | Nov 09, 2020 |  |
| Rune Labs | Rune Labs is a software and data platform for neuromodulation and brain therapies of the future. The platform's software-as-a-service platform works with existing and emerging neuromodulation systems to manage complex therapies and get the most value out of available data. Their cloud-based software platform provides these therapy developersthe performance, scalability, and availability they need to run complex therapy algorithms across many patients, deliver precision medicine, and identify likely responders for clinical trials.Rune Labs was founded in 2018 and is headquartered in San Francisco, California. | $5M | Seed | Oct 26, 2020 |  |
| G-Tech Medical | G-Tech Medical is developing a wireless, wearable, disposable electrode patch to measure the electrical activity from the stomach, small intestine and colon. Most patients with abdominal pain, constipation, diarrhea or bloating have functional disorders that are not diagnosed with colonoscopies or CT scans. G-Tech's GutCheck patch will measuremotor activity and thus evaluate motility to allow physicians to better target the treatment. |  | Series A | May 21, 2020 |  |

10 of 19 investments shown.

## Co-investors
- [Artis Ventures](https://shizune.co/investors/profile/artis) — VC Fund, 3 deals together
- [Moment Ventures](https://shizune.co/investors/profile/moment-ventures) — VC Fund, 3 deals together
- [Eclipse](https://shizune.co/investors/profile/eclipse-ventures) — VC Fund, 2 deals together
- [Mayfield Fund](https://shizune.co/investors/profile/mayfield-fund) — VC Fund, 2 deals together
- [Mayo Clinic](https://shizune.co/investors/profile/mayoclinic) — VC Fund, 2 deals together
- [NTT Venture Capital](https://shizune.co/investors/profile/nttvc) — VC Fund, 2 deals together

## About DigiTx Partners

VC Fund · Brisbane, United States

At DigiTx Partners,we believe that the pace of change in healthcare will only accelerate in the coming years. We believe that there are many smart people with great insights and drive who are developing innovative technologies and solutions. We look forward to supporting innovative companies that will make a difference in our healthcareecosystem, from companies that will change how patients navigate the healthcare system, that will integrate the disparate elements that comprise both diagnosis and treatment, that will speed the development of more effective drugs and that will enhance and enable efficient and accurate physician-patient interaction. DigiTx Partners looks forward to investing in those digital health companies that strive to keep all of us in better health.

2 contacts available at DigiTx Partners.

| Name | Title | Profile |
| --- | --- | --- |
| David Kim | CEO & Managing Director | https://shizune.co/investors/profile/david-kim-3 |
| Miraj Sanghvi | Partner | https://shizune.co/investors/profile/miraj-sanghvi |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does David Kim invest in?

David Kim invests primarily in Health Care, Medical Device and Artificial Intelligence startups, most often at Series A and Seed stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did David Kim last invest?

The most recent investment recorded for David Kim closed in May 2024. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co